1. AS602801, an Anti-Cancer Stem Cell Drug Candidate, Suppresses Gap-junction Communication Between Lung Cancer Stem Cells and Astrocytes.
- Author
-
Kuramoto K, Yamamoto M, Suzuki S, Sanomachi T, Togashi K, Seino S, Kitanaka C, and Okada M
- Subjects
- A549 Cells, Animals, Astrocytes drug effects, Astrocytes metabolism, Brain Neoplasms prevention & control, Cell Communication drug effects, Down-Regulation, Gap Junctions drug effects, Gene Expression Regulation, Neoplastic drug effects, Humans, Lung Neoplasms drug therapy, Neoplastic Stem Cells drug effects, Neoplastic Stem Cells metabolism, Rats, Astrocytes cytology, Benzothiazoles pharmacology, Connexin 43 metabolism, Lung Neoplasms metabolism, Neoplastic Stem Cells cytology, Pyrimidines pharmacology
- Abstract
Background/aim: Cancer stem cells (CSCs) are associated with tumorigenesis, recurrence, and metastasis. Cell-cell communication via gap junctions (GJs) between metastatic cancer cells and astrocytes is necessary for brain metastasis. Agents targeting communication between CSCs and astrocytes are expected to suppress brain metastasis., Materials and Methods: Using the A549 CSC, a cancer stem-like cell derived from A549, we examined the effect of AS602801, an anti-cancer stem cell agent whose safety has been confirmed in a phase 2 clinical trial, on GJ communication and connexin expression using a dye-transfer assay and immunoblot analysis, respectively., Results: AS602801 specifically suppressed cell-cell communication in A549 CSCs without any suppression of GJ communication in astrocytes; it also decreased the expression of connexin 43, a constituent of GJs, in A549 CSCs., Conclusion: The anti-cancer stem cell agent, AS602801, is a potential drug candidate against brain metastasis., (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF